Hua Fang

Jack Chen is Scientific Director of Translational Oncology, Precision Medicine at AbbVie, where he leads efforts to integrate biomarker strategies into oncology drug development, with a particular focus on ADCs and immuno‑oncology programs. He oversees cross‑functional teams driving translational research from preclinical discovery through early clinical studies. Jack brings over a decade of biopharma experience, including leadership roles at Pfizer, OncoMed, and Eli Lilly in cancer biology and immunotherapy. He holds a PhD from Johns Hopkins University and combines deep scientific expertise with a strong focus on precision medicine to advance targeted cancer treatments.